The cross-talk between tumor-associated macrophages and tumor endothelium: Recent advances in macrophage-based cancer immunotherapy.

Antineoplastic Agents, Immunological / therapeutic use Endothelial Cells Humans Immunotherapy / methods Neoplasms / drug therapy Receptor Cross-Talk Tumor Microenvironment Tumor-Associated Macrophages / metabolism
Angiogenesis Cancer Endothelial cells Tumor microenvironment Tumor-associated macrophages

Journal

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295

Informations de publication

Date de publication:
Feb 2022
Historique:
received: 19 11 2021
revised: 21 12 2021
accepted: 23 12 2021
entrez: 22 1 2022
pubmed: 23 1 2022
medline: 17 3 2022
Statut: ppublish

Résumé

Tumor-associated macrophages (TAMs) are among the abundant cell populations of the tumor microenvironment (TME), which have pivotal roles in tumor development, chemoresistance, immune evasion, and metastasis. Growing evidence indicates that TAMs and the cross-talk between TAMs and tumoral endothelial cells can substantially contribute to tumor angiogenesis, which is considered a vital process for cancer development. Besides, tumoral endothelial cells can regulate the leukocyte infiltration to the TME in solid cancers and contribute to immune evasion. Therefore, targeting the immunosuppressive TAMs and the cross-talk between them can be a promising strategy for improving anti-tumoral immune responses. This review aims to summarize the biology of TAMs, their recently identified roles in tumor development/angiogenesis, and recent advances in macrophage-based cancer immunotherapy approaches for treating cancers.

Identifiants

DOI: 10.1016/j.biopha.2021.112588 PMID: 35062062
pubmed: 35062062
pii: S0753-3322(21)01375-5
doi: 10.1016/j.biopha.2021.112588
pii:
doi:

Substances chimiques

Antineoplastic Agents, Immunological 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

112588

Informations de copyright

Copyright © 2021. Published by Elsevier Masson SAS.

Auteurs

Ali Baradaran (A)

Diamantina Institute, Translational Research Institute, The University of Queensland, Brisbane, QLD, Australia; Research & Development, BSD Robotics, Queensland, Australia.

Zahra Asadzadeh (Z)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Nima Hemmat (N)

Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.

Amir Baghbanzadeh (A)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Mahdi Abdoli Shadbad (MA)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.

Neda Khosravi (N)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Afshin Derakhshani (A)

Experimental Pharmacology Laboratory, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.

Hajar Alemohammad (H)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Mina Afrashteh Nour (M)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Hossein Safarpour (H)

Cellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand, Iran.

Nicola Silvestris (N)

Medical Oncology Unit-IRCCS IstitutoTumori "Giovanni Paolo II" of Bari, Bari, Italy; Department of Biomedical Sciences and Human Oncology DIMO-University of Bari, Bari, Italy.

Oronzo Brunetti (O)

Medical Oncology Unit-IRCCS IstitutoTumori "Giovanni Paolo II" of Bari, Bari, Italy. Electronic address: o.brunetti@oncologico.bari.it.

Behzad Baradaran (B)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Neurosciences Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: baradaranb@tbzmed.ac.ir.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Antinéoplasiques immunologiques › The cross-talk between tumor-associated...
questionsmedicales.fr › Cellules › Cellules épithéliales › Cellules endothéliales › The cross-talk between tumor-associated...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › The cross-talk between tumor-associated...
questionsmedicales.fr › Thérapeutique › Biothérapie › Immunothérapie › The cross-talk between tumor-associated...
questionsmedicales.fr › Tumeurs › The cross-talk between tumor-associated...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Interactions entre récepteurs › The cross-talk between tumor-associated...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Microenvironnement cellulaire › Microenvironnement tumoral › The cross-talk between tumor-associated...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Phagocytes › Macrophages › Macrophages associés aux tumeurs › The cross-talk between tumor-associated...